Select Bibliography

Filter by any of these (after searching):

Br J Haematol

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 9 items

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).

Advani, Ranjana H , Chen, Haiyan , Habermann, Thomas M ... - - Br J Haematol - 2010

Manuscript - Secondary-not-in-original - Primary - Older Adult - C9793

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia

Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Nicolet, Deedra ... - - Br J Haematol - 2016

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-9222 , CALGB-9621 , CALGB-9720

Akt Inhibitor MK2206 Selectively Targets CLL B-cell Receptor Induced Cytokines, Mobilizes Lymphocytes and Synergizes with Bendamustine to Induce CLL Apoptosis

Ding, Wei , Shanafelt, Tait D. , Lesnick, Connie E. ... - - Br J Haematol - 2014

Manuscript - Primary - Primary - Leukemia - N1087

Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51

McPhail, Ellen R. , Law, Mark E. , Decker, Paul A. ... - - Br J Haematol - 2011

Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - NCCTG-86-72-52 , 93-73-51 , 96-73-51

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002

Rizzieri, David A. , Johnson, Jeffrey L. , Byrd, John C. ... - - Br J Haematol - 2014

Manuscript - Primary - Primary - Leukemia - CALGB-10002

Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).

Rosenbaum, Cara A , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Br J Haematol - 2019

Manuscript - Primary - Primary - Lymphoma - CALGB-50901

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

Sborov, Douglas W. , Baljevic, Muhamed , Reeves, Brandi ... - - Br J Haematol - 2022

Manuscript - Secondary-not-in-original - Primary - Myeloma - AFT-29 (GRIFFIN)

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

Smith, Sonali M , Grinblatt, David , Johnson, Jeffrey L ... - - Br J Haematol - 2008

Manuscript - Primary - Primary - Lymphoma - CALGB-50002

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Voorhees, Peter M. , Orlowski, Robert Z. , Mulkey, Flora ... - - Br J Haematol - 2015

Manuscript - Primary - Primary - Leukemia - CALGB-10301